Lv2
145 积分 2021-04-26 加入
Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response
4天前
已完结
Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy
11天前
已完结
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
11天前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
13天前
已完结
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
14天前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
15天前
已完结
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA -mutant breast cancer
15天前
已完结
Developing selective PI3K degraders to modulate both kinase and non-kinase functions
15天前
已完结
Targeted protein degradation: from mechanisms to clinic
19天前
已完结
Protein degraders enter the clinic — a new approach to cancer therapy
19天前
已完结
皖公网安备34019202002308
